NASDAQ: ASRT | Healthcare / Drug Manufacturers / USA |
2.53 | +0.1100 | +4.55% | Vol 1.11M | 1Y Perf 4.76% |
Oct 4th, 2023 16:00 DELAYED |
BID | 2.44 | ASK | 2.55 | ||
Open | 2.42 | Previous Close | 2.42 | ||
Pre-Market | - | After-Market | 2.53 | ||
- - | - -% |
Target Price | 6.94 | Analyst Rating | Strong Buy 1.33 | |
Potential % | 174.31 | Finscreener Ranking | ★★★ 48.64 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★★ 55.55 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★+ 56.14 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 7.67 | Earnings Rating | Sell | |
Market Cap | 142.99M | Earnings Date | 14th Nov 2023 | |
Alpha | 0.02 | Standard Deviation | 0.27 | |
Beta | 0.42 |
Today's Price Range 2.392.54 | 52W Range 2.078.01 | 5 Year PE Ratio Range -3.0013.10 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -4.17% | ||
1 Month | -22.63% | ||
3 Months | -52.44% | ||
6 Months | -57.90% | ||
1 Year | 4.76% | ||
3 Years | -7.80% | ||
5 Years | -88.86% | ||
10 Years | -91.62% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -36.27 | |||
ROE last 12 Months | 22.16 | |||
ROA (5Y Avg) | -14.84 | |||
ROA last 12 Months | 8.25 | |||
ROC (5Y Avg) | -3.97 | |||
ROC last 12 Months | 18.04 | |||
Return on invested Capital Q | 3.08 | |||
Return on invested Capital Y | 3.89 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 1.00 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
7.90 | ||||
1.56 | ||||
1.86 | ||||
3.80 | ||||
6.00 | ||||
1.14 | ||||
-3.71 | ||||
2.79 | ||||
213.89M | ||||
Forward PE | 5.33 | |||
PEG | 1.13 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.20 | ||||
1.40 | ||||
0.33 | ||||
0.51 | ||||
4.00 | ||||
Leverage Ratio | 2.60 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
87.50 | ||||
26.40 | ||||
49.70 | ||||
-28.00 | ||||
19.90 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
105.88M | ||||
2.19 | ||||
-23.33 | ||||
-25.90 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2023 | 0.14 | 0.13 | -7.14 |
Q01 2023 | 0.13 | -0.07 | -153.85 |
Q04 2022 | 0.23 | 1.34 | 482.61 |
Q03 2022 | 0.07 | 0.08 | 14.29 |
Q02 2022 | 0.08 | 0.16 | 100.00 |
Q01 2022 | 0.09 | 0.20 | 122.22 |
Q04 2021 | 0.12 | 0.10 | -16.67 |
Q03 2021 | -0.04 | 0.08 | 300.00 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
9/2023 QR | 0.13 | -7.14 | Negative |
12/2023 QR | 0.12 | 0.00 | - |
12/2023 FY | 0.66 | 83.33 | Positive |
12/2024 FY | 0.48 | -27.27 | Negative |
Next Report Date | 14th Nov 2023 |
Estimated EPS Next Report | 0.13 |
Estimates Count | 2 |
EPS Growth Next 5 Years % | 7.00 |
Volume Overview | |
---|---|
Volume | 1.11M |
Shares Outstanding | 56.52K |
Shares Float | 52.05M |
Trades Count | 7.46K |
Dollar Volume | 2.79M |
Avg. Volume | 1.73M |
Avg. Weekly Volume | 1.36M |
Avg. Monthly Volume | 1.72M |
Avg. Quarterly Volume | 2.11M |
Assertio Holdings Inc. (NASDAQ: ASRT) stock closed at 2.42 per share at the end of the most recent trading day (a -1.22% change compared to the prior day closing price) with a volume of 1.24M shares and market capitalization of 142.99M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 27 people. Assertio Holdings Inc. CEO is Daniel A. Peisert.
The one-year performance of Assertio Holdings Inc. stock is 4.76%, while year-to-date (YTD) performance is -41.16%. ASRT stock has a five-year performance of -88.86%. Its 52-week range is between 2.0747 and 8.01, which gives ASRT stock a 52-week price range ratio of 7.67%
Assertio Holdings Inc. currently has a PE ratio of 7.90, a price-to-book (PB) ratio of 1.56, a price-to-sale (PS) ratio of 1.86, a price to cashflow ratio of 3.80, a PEG ratio of 1.13, a ROA of 8.25%, a ROC of 18.04% and a ROE of 22.16%. The company’s profit margin is 19.90%, its EBITDA margin is 49.70%, and its revenue ttm is $105.88 Million , which makes it $2.19 revenue per share.
Of the last four earnings reports from Assertio Holdings Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.13 for the next earnings report. Assertio Holdings Inc.’s next earnings report date is 14th Nov 2023.
The consensus rating of Wall Street analysts for Assertio Holdings Inc. is Strong Buy (1.33), with a target price of $6.94, which is +174.31% compared to the current price. The earnings rating for Assertio Holdings Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Assertio Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Assertio Holdings Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 24.15, ATR14 : 0.14, CCI20 : -96.68, Chaikin Money Flow : -0.33, MACD : -0.27, Money Flow Index : 19.39, ROC : -12.16, RSI : 23.53, STOCH (14,3) : 0.00, STOCH RSI : 0.00, UO : 26.38, Williams %R : -100.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Assertio Holdings Inc. in the last 12-months were: Ajay Patel (Option Excercise at a value of $0), Ajay Patel (Sold 64 313 shares of value $195 512 ), Daniel A. Peisert (Option Excercise at a value of $0), James L. Tyree (Sold 43 143 shares of value $258 858 ), Mason Heather (Sold 89 286 shares of value $651 788 ), Paul Schwichtenberg (Option Excercise at a value of $0), Sam Schlessinger (Option Excercise at a value of $0), Schlessinger Sam (Option Excercise at a value of $0), Schlessinger Sam (Sold 45 236 shares of value $137 517 ), Schwichtenberg Paul (Option Excercise at a value of $0), Schwichtenberg Paul (Sold 104 980 shares of value $322 289 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
CEO: Daniel A. Peisert
Telephone: +1 224 419-7106
Address: 100 South Saunders Road, Lake Forest 60045, IL, US
Number of employees: 27
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.